Quantcast
Last updated on April 18, 2014 at 13:58 EDT

Latest Phenols Stories

2014-01-27 23:27:22

Justin Hoffman, nephew of counter-culture icon Abbie Hoffman, credits his second chance at life to the powerful spiritual, physical and holistic healing programs of The Holistic Sanctuary. Los Angeles, CA (PRWEB) January 27, 2014 "My brain was healing itself, while Johnny was standing over me performing a life-changing, spiritual healing session. For the first time in 25 years, I could feel my soul!" These are words from Justin Hoffman as he experienced the healing power of the...

2014-01-23 16:25:23

MALVERN, Pa. and RALEIGH, N.C., Jan. 23, 2014 /PRNewswire/ -- Endo Pharmaceuticals Inc., a subsidiary of Endo Health Solutions Inc. (Nasdaq: ENDP), and BioDelivery Sciences International, Inc. (Nasdaq: BDSI) announced today positive top-line results from its pivotal Phase 3 efficacy study of BEMA buprenorphine in opioid- "naive" subjects. BEMA buprenorphine is being developed for the treatment of moderate to severe chronic pain in patients requiring around-the-clock opioid therapy for...

2014-01-23 16:24:57

FORT WASHINGTON, Pa., Jan., 23, 2014 /PRNewswire-USNewswire/ -- This year, Americans will suffer approximately one billion colds[1] and as many as one in five Americans will suffer from the flu.[2] For the millions of Americans who will turn to over-the-counter (OTC) medicines for relief, McNeil Consumer Healthcare ("McNeil"), the maker of TYLENOL®, has launched an enhanced consumer education website, GETRELIEFRESPONSIBLY.COM, to help sufferers get relief from their symptoms responsibly....

2014-01-21 23:27:11

“2014 Deep Research Report on Global and China Propofol Industry” and “2014 Deep Research Report on Global And China Nucleotide Industry” are the new research reports added to the online library of DeepResearchReports.com. Dallas, Texas (PRWEB) January 21, 2014 2014 Deep Research Report on Global And China Nucleotide Industry is a professional and in-depth study on the current state of the nucleotide industry in Global and China. The report provides a basic overview of the...

2014-01-16 23:25:01

The Holistic Sanctuary is shattering traditional addiction treatment philosophies, providing hope and permanent life changing results through its new, proprietary and all natural “Pouyan Method” treatment protocol. Baja, CA (PRWEB) January 16, 2014 The Holistic Sanctuary is quickly becoming the therapeutic destination of choice for addicts who have experienced little or no success at traditional treatment centers, where treatment is prescribed based on the belief addiction is a...

2014-01-15 16:23:31

"RVX-208 treated patients have significant lower MACE events in high risk CVD patients" TSX Exchange Symbol: RVX CALGARY, Jan. 15, 2014 /PRNewswire/ - Resverlogix Corp. (TSX: RVX) today announced new information arising from its ongoing analysis of data from both the SUSTAIN and ASSURE trials in atherosclerotic patients with high risk for recurrent events. This analysis, performed by an independent firm focuses on the potential benefit of RVX-208, a first in class...

2014-01-10 08:23:03

BEMA Buprenorphine Phase 3 opioid naive study database lock imminent; triggers $10M milestone payment from Endo Pharmaceuticals RALEIGH, N.C., Jan. 10, 2014 /PRNewswire/ -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI) announced updates to the company's anticipated 2014 milestones for its product portfolio, including the imminent database lock for the Phase 3 clinical study of BEMA Buprenorphine for the treatment of moderate to severe chronic pain in opioid naive subjects, with...

2014-01-09 12:26:30

CORALVILLE, Iowa, Jan. 9, 2014 /PRNewswire/ -- KemPharm, Inc., a clinical stage biopharmaceutical company focused on the discovery and development of new, safer therapies to treat pain, announced today that president and CEO, Travis Mickle, Ph.D. will present at the Biotech Showcase(TM) 2014 Conference being held in San Francisco January 13-15, 2014. Among the topics to be discussed, Dr. Mickle will provide an overview of KemPharm's development pipeline, including KP201, the...

2014-01-09 08:26:46

- Company awarded 180 days marketing exclusivity on the 360 mg strength - PITTSBURGH, Jan. 9, 2014 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that its U.S.-based subsidiary Mylan Pharmaceuticals Inc. has launched Mycophenolic Acid Delayed-release Tablets, 180 mg and 360 mg. This product is the generic version of Novartis' Myfortic(®) Delayed-release Tablets. Mylan was the first company to have filed a substantially complete Abbreviated New Drug Application (ANDA)...

2014-01-08 20:21:27

- Patient safety and well-being are highest priority at Novartis Pharmaceuticals Corporation (NPC) EAST HANOVER, N.J., Jan. 8, 2014 /PRNewswire/ -- Patient safety and well-being are the highest priority at Novartis Pharmaceuticals Corporation (NPC). NPC is dedicated to improving patient health and supports patient medication adherence programs integral to this goal. These include outreach by pharmacies aimed at helping patients appropriately take their medicines as prescribed...